黄芪注射液联合重组人促红细胞生成素对血液透析患者红细胞免疫功能的影响

目的 观察黄芪注射液联合重组人促红细胞生成素(rHuEPO)对血液透析患者红细胞免疫功能的影响.方法 51例慢性肾衰竭尿毒症行血液透析维持治疗的患者,按随机数字表法分为治疗组(26例)与对照组(25例).治疗组在透析液A液中加入黄芪注射液1 ml/kg,对照组不使用黄芪注射液.测定治疗前后IgG、IgA、IgM、红细胞C3b受体花环率(RBC-C3bRR)、红细胞免疫复合物花环率(RBC-ICR)、CD35阳性红细胞百分率、红细胞超氧化物歧化酶(SOD)水平.结果 治疗8周后,治疗组IgG、IgA、IgM水平及对照组IgG、IgA水平显著高于治疗前(P<0.01);治疗组治疗8周后IgM水平为(2.03±0.73)g/L,与对照组比较差异有统计学意义(P<0.05).两组RBC-C3bRR、CD35阳性红细胞百分率、SOD水平治疗8周后显著高于治疗前,RBC-ICR水平显著低于治疗前(P<0.05);治疗组治疗8周后,RBC-C3bRR为(10.85±2.31)%,显著高于对照组,RBC-ICR为(5.34±1.91)%,显著低于对照组(P<0.05).结论 黄芪注射液联合rHuEPO可提高血液透析患者血清免疫球蛋白水平,提高红细胞免疫功能,较单用r-HuEPO效果更好.

Effects of astragalus membranaceus parenteral solution combined with recombinant human erythropietin on erythrocyte immunity function in patients with hemodialysis

Objective To investigate the effects of astragalus membranaceus parenteral solution combined with recombinant human erythropietin (rHuEPO) on erythrocyte immunity function in patients with hemodialysis. Methods Fifty-one patients of chronic renal failure(CRF) with hemodialysis were divided into 2 groups randomly according to whether treated with astragalus membranaceus parenteral solution or not(therapeutic group, was 26 cases and control group was 25 cases). IgG, IgA, IgM, RBC-C3b,RR,RBC-ICR, erythrocyte percentage of CD35 positive and SOD was measured before treatment and 8 weeks after treatment. Results After 8 weeks' treatment, IgG,IgA,IgM levels in therapeutic group and IgG,IgA levels in control group were higher than those before treatment(P < 0.01 ). IgM (2.03±0.73 ) g/L ] was higher than that in control group (P< 0.05). RBC-C3B,RR, erythrocyte percentage of CD35 positive and SOD were higher and RBC-ICR was lower than those before treatment in two groups (P < 0.05 ) ;compared with that in control group, RBC-C3b, RR was higher (10.85±2.31 )% ] and RBC-ICR was lower (5.34±1.91 )% ] (P < 0.05 ).Conclusion Astragalus membranaceus parenteral solution combined with rHuEPO is superior to improve CRF patients' levels of immune globulin and erythrecyte immunity function.